Detalhe da pesquisa
1.
Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.
Br J Cancer
; 123(3): 495, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393850
2.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer
; 125(23): 4172-4180, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483485
3.
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.
Br J Cancer
; 120(1): 88-96, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377341
4.
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Future Oncol
; 14(14): 1387-1396, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29421926
5.
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Future Oncol
; 12(12): 1469-81, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26997579
6.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Cancer
; 126(12): 2935-2937, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154908
7.
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Oncologist
; 20(10): 1132-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26336083
8.
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Ann Hematol
; 93(3): 403-9, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23955074
9.
Jeffrey Vacirca on How the COA Advocates for Community Oncology Practices and Patients.
Oncology (Williston Park)
; 31(7): 518-20, 2017 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28712095
10.
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Am Health Drug Benefits
; 14(3): 1-7, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261710
11.
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Am Health Drug Benefits
; 14(4): 133-139, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261717
12.
The authors respond.
Oncology (Williston Park)
; 28(3): 178, C3, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24855723
13.
Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
J Infus Nurs
; 42(5): 260-263, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464835
14.
The 340b drug discount program: oncology's optical illusion.
Oncology (Williston Park)
; 27(11): 1068, 1070, 1072, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24575533
15.
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Cancer Med
; 7(5): 1660-1669, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573207
16.
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Nat Commun
; 9(1): 1219, 2018 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572535
17.
Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
J Gastrointest Cancer
; 48(1): 103-109, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028766
18.
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
Cancer Manag Res
; 9: 179-187, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28579832
19.
The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/inhibition of platelet aggregation.
Thromb Haemost
; 93(2): 326-30, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15711750
20.
Reversible posterior leukoencephalopathy syndrome after rituximab.
Am J Emerg Med
; 28(4): 537.e1-2, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20466257